KR20030010724A - 방출 pH 범위 및/또는 속도 제어 조성물 - Google Patents
방출 pH 범위 및/또는 속도 제어 조성물 Download PDFInfo
- Publication number
- KR20030010724A KR20030010724A KR1020027017110A KR20027017110A KR20030010724A KR 20030010724 A KR20030010724 A KR 20030010724A KR 1020027017110 A KR1020027017110 A KR 1020027017110A KR 20027017110 A KR20027017110 A KR 20027017110A KR 20030010724 A KR20030010724 A KR 20030010724A
- Authority
- KR
- South Korea
- Prior art keywords
- release
- compound
- polymer
- range
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (16)
- (ⅰ) 화학식 (Ⅰ)의 티에노트리아졸로디아제핀 화합물, 그의 약제학적으로 허용되는 염 또는 그의 수화물; 및 (ⅱ) 수용성 고분자, 장용성 고분자, 수불용성 고분자 및 다공성 고분자로부터 선택되는 적어도 1종의 기제를 함유하는, 방출 pH 영역 및/또는 방출속도 제어 조성물:상기 식에서,X는 할로겐이고, R1은 C1-C4알킬이며, R2는 C1-C4알킬이고, a는 1-4의 정수이며, R3는 C1-C4알킬, C1-C4하이드록시알킬, C1-C4알콕시, 임의로 치환체(들)를 갖는 페닐 또는 임의로 치환체(들)를 갖는 헤테로아릴이다.
- 제1항에 있어서, 계면활성제를 추가로 함유하는 방출 pH 영역 및/또는 방출속도 제어 조성물.
- 화학식 (Ⅰ)의 화합물, 그의 약제학적으로 허용되는 염 또는 그의 수화물, 및 계면활성제를 포함하는, 방출 pH 영역 및/또는 방출속도 제어 조성물.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 화학식 (Ⅰ)의 화합물이 (S)-2-[4-(4-클로로페닐)-2,3,9-트리메틸-6H-티에노[3,2-f][1,2,4]트리아졸로[4,3-a] [1,4]디아제핀-6-일]-N-(4-하이드록시페닐)아세트아미드인 방출 pH 영역 및/또는 방출속도 제어 조성물.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 소화관관강의 중성 영역에서의 염증성 질환의 치료제인 방출 pH 영역 및/또는 방출속도 제어 조성물.
- 제5항에 있어서, 염증성 질환이 궤양성 대장염 또는 크론병인 방출 pH 영역 및/또는 방출속도 제어 조성물.
- 화학식 (Ⅰ)의 화합물, 그의 약제학적으로 허용되는 염 또는 그의 수화물과 고분자를 용매중에 용해 또는 분산시키고, 용매를 증발시키는 것을 포함하는, 방출 pH 영역 및/또는 방출속도 제어 조성물의 제조방법.
- 제7항에 있어서, 고분자가 수용성 고분자, 장용성 고분자, 수난용성 고분자및 다공성 고분자로 구성된 그룹으로부터 선택되는 적어도 1종인 방법.
- 제7항 또는 제8항에 있어서, 계면활성제를 용매에 용해 또는 분산시키는 것을 추가로 포함하는 방법.
- 화학식 (Ⅰ)의 화합물, 그의 약제학적으로 허용되는 염 또는 그의 수화물과 계면활성제를 용매중에 용해 또는 분산시키고, 용매를 증발시키는 것을 포함하는, 방출 pH 영역 및/또는 방출속도 제어 조성물의 제조방법.
- 제7항 내지 제10항 중 어느 한 항의 방법에 의해 수득할 수 있는, 방출 pH 영역 및/또는 방출속도 제어 조성물.
- 화학식 (Ⅰ)의 화합물, 그의 약제학적으로 허용되는 염 또는 그의 수화물을 용융시키고, 고분자를 용해 또는 분산시킨 후, 냉각 고화시키는 것을 포함하는, 방출 pH 영역 및/또는 방출속도 제어 조성물의 제조방법.
- 제12항에 있어서, 고분자가 수용성 고분자, 장용성 고분자, 수불용성 고분자 및 다공성 고분자로 구성된 그룹으로부터 선택되는 적어도 1종인 방법.
- 제12항 또는 제13항에 있어서, 계면활성제를 용융 산물에 용해 또는 분산시키는 것을 추가로 포함하는 방법.
- 화학식 (Ⅰ)의 화합물, 그의 약제학적으로 허용되는 염 또는 그의 수화물을 용융시키고, 계면활성제를 용해 또는 분산시킨 후, 냉각 고화하는 것을 포함하는, 방출 pH 영역 및/또는 방출속도 제어 조성물의 제조방법.
- 제12항 내지 제15항 중 어느 한 항의 방법에 의해 수득할 수 있는 방출 pH 영역 및/또는 방출속도 제어 조성물.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPJP-P-2000-00182293 | 2000-06-16 | ||
JP2000182293 | 2000-06-16 | ||
PCT/JP2001/005151 WO2001095912A1 (en) | 2000-06-16 | 2001-06-15 | COMPOSITIONS CONTROLLING RELEASE pH RANGE AND/OR SPEED |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030010724A true KR20030010724A (ko) | 2003-02-05 |
KR100838686B1 KR100838686B1 (ko) | 2008-06-16 |
Family
ID=18683084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027017110A KR100838686B1 (ko) | 2000-06-16 | 2001-06-15 | 방출 pH 범위 및/또는 속도 제어 조성물 |
Country Status (7)
Country | Link |
---|---|
US (4) | US20030130268A1 (ko) |
EP (1) | EP1297836A4 (ko) |
JP (1) | JP4875277B2 (ko) |
KR (1) | KR100838686B1 (ko) |
AU (1) | AU2001264303A1 (ko) |
CA (1) | CA2412776C (ko) |
WO (1) | WO2001095912A1 (ko) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006056781A (ja) * | 2002-11-15 | 2006-03-02 | Bioserentack Co Ltd | 界面活性剤を含む固形化製剤 |
JP2004339162A (ja) * | 2003-05-16 | 2004-12-02 | Shin Etsu Chem Co Ltd | 難溶性薬物を含む医薬用固形製剤とその製造方法 |
JP5576922B2 (ja) * | 2006-04-20 | 2014-08-20 | 信越化学工業株式会社 | 腸溶性固体分散体を含んでなる固形製剤 |
JP2007308480A (ja) * | 2006-04-20 | 2007-11-29 | Shin Etsu Chem Co Ltd | 腸溶性固体分散体を含んでなる固形製剤 |
JP2010189337A (ja) * | 2009-02-19 | 2010-09-02 | Asahi Breweries Ltd | 難溶性物質を含有する顆粒、錠剤、及び難溶性物質の可溶化方法 |
US20100319928A1 (en) * | 2009-06-22 | 2010-12-23 | Baker Hughes Incorporated | Through tubing intelligent completion and method |
US20110000674A1 (en) * | 2009-07-02 | 2011-01-06 | Baker Hughes Incorporated | Remotely controllable manifold |
US20110073323A1 (en) * | 2009-09-29 | 2011-03-31 | Baker Hughes Incorporated | Line retention arrangement and method |
BR122014024883A2 (pt) | 2010-05-14 | 2019-08-20 | Dana-Farber Cancer Institute, Inc. | Compostos no tratamento de neoplasia |
WO2011143657A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
BR112012029057A2 (pt) | 2010-05-14 | 2020-10-13 | Dana-Farber Cancer Institute, Inc. | composições e métodos de tratamento de leucemia |
WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
EP2705039B1 (en) | 2011-05-04 | 2017-07-26 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
EP2721031B1 (en) | 2011-06-17 | 2016-01-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
IN2015DN03135A (ko) * | 2012-09-28 | 2015-10-02 | Oncoethix Sa | |
US9975896B2 (en) | 2013-07-25 | 2018-05-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
US9795612B2 (en) | 2013-08-01 | 2017-10-24 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
CN105899212A (zh) * | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
WO2015018523A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A novel bet-brd inhibitor for treatment of solid tumors |
WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
CN105849110B (zh) | 2013-11-08 | 2019-08-02 | 达纳-法伯癌症研究所有限公司 | 使用溴结构域和额外终端(bet)蛋白抑制剂的用于癌症的组合疗法 |
WO2015078931A1 (en) * | 2013-11-27 | 2015-06-04 | Oncoethix Sa | Method of treating neuroblastomas using thienotriazolodiazepine compounds |
EP3074018A1 (en) * | 2013-11-27 | 2016-10-05 | Oncoethix GmbH | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds |
CN105813643A (zh) * | 2013-11-27 | 2016-07-27 | 翁科埃斯克斯有限公司 | 利用含有噻吩并三唑二氮杂*化合物的药物制剂治疗非小细胞肺癌的方法 |
JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ジアゼパン誘導体の使用 |
WO2015117053A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
RU2722179C2 (ru) | 2014-02-28 | 2020-05-28 | Тэнша Терапеутикс, Инк. | Лечение состояний, ассоциированных с гиперинсулинемией |
KR20160145833A (ko) | 2014-05-02 | 2016-12-20 | 온코에틱스 게엠베하 | 티에노트리아졸로디아제핀 화합물을 사용한 급성 골수성 백혈병 및/또는 급성 림프아구성 백혈병의 치료 방법 |
EP3137086A4 (en) * | 2014-05-02 | 2017-12-27 | Oncoethix GmbH | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds |
WO2015169953A1 (en) | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Method of treating glioma using thienotriazolodiazepine compounds |
WO2015169951A1 (en) | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds |
US9901583B2 (en) | 2014-06-13 | 2018-02-27 | Oncoethix Gmbh | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds |
ES2725928T3 (es) | 2014-06-20 | 2019-09-30 | Constellation Pharmaceuticals Inc | Formas cristalinas de 2-((4S)-6-(4-clorofenil)-1-metil-4H-benzo[c]isoxazolo[4,5-e]azepin-4-il)acetamida |
WO2016022902A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
CN106793775B (zh) | 2014-08-08 | 2020-06-02 | 达纳-法伯癌症研究所股份有限公司 | 二氢碟啶酮衍生物及其用途 |
EP3182976A1 (en) * | 2014-08-19 | 2017-06-28 | Oncoethix GmbH | Methods of treating lymphoma using thienotriazolodiazepine compounds |
EP3185871A1 (en) * | 2014-08-28 | 2017-07-05 | Oncoethix GmbH | Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine compounds |
EP3212654B1 (en) | 2014-10-27 | 2020-04-08 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
WO2016176335A1 (en) | 2015-04-27 | 2016-11-03 | Concert Pharmaceuticals, Inc. | Deuterated otx-015 |
WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
US10881668B2 (en) | 2015-09-11 | 2021-01-05 | Dana-Farber Cancer Institute, Inc. | Acetamide thienotriazolodiazepines and uses thereof |
CA2996974A1 (en) | 2015-09-11 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
AU2016361478B2 (en) | 2015-11-25 | 2020-09-10 | Dana-Farber Cancer Institute, Inc. | Bivalent bromodomain inhibitors and uses thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56110612A (en) * | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Readily disintegrable and absorbable compression molded article of slightly soluble drug |
US5264446A (en) | 1980-09-09 | 1993-11-23 | Bayer Aktiengesellschaft | Solid medicament formulations containing nifedipine, and processes for their preparation |
FR2525108B1 (fr) | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
JPS5914446A (ja) | 1982-07-13 | 1984-01-25 | Michio Yoshikawa | 過負荷検出装置 |
IE63321B1 (en) * | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
JP2773959B2 (ja) * | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
WO1994006802A1 (en) * | 1992-09-18 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compound and medicinal use thereof |
US5686105A (en) * | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
JPH07223970A (ja) * | 1994-02-10 | 1995-08-22 | Tanabe Seiyaku Co Ltd | 消化管内適所放出製剤 |
JPH07324086A (ja) * | 1994-05-31 | 1995-12-12 | Sankyo Co Ltd | チアゾリジン誘導体の固体分散体または固体分散体製剤 |
JPH08143476A (ja) * | 1994-11-18 | 1996-06-04 | Japan Tobacco Inc | 薬物放出制御膜及び固形製剤 |
SG80553A1 (en) * | 1995-07-20 | 2001-05-22 | Tanabe Seiyaku Co | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
EP0989131B1 (en) * | 1996-09-13 | 2002-11-13 | Mitsubishi Pharma Corporation | Thienotriazolodiazepine compounds and medicinal uses thereof |
-
2001
- 2001-06-15 CA CA2412776A patent/CA2412776C/en not_active Expired - Lifetime
- 2001-06-15 EP EP01938708A patent/EP1297836A4/en not_active Withdrawn
- 2001-06-15 KR KR1020027017110A patent/KR100838686B1/ko active IP Right Grant
- 2001-06-15 AU AU2001264303A patent/AU2001264303A1/en not_active Abandoned
- 2001-06-15 WO PCT/JP2001/005151 patent/WO2001095912A1/ja active Application Filing
- 2001-06-15 JP JP2002510090A patent/JP4875277B2/ja not_active Expired - Fee Related
-
2002
- 2002-12-16 US US10/319,568 patent/US20030130268A1/en not_active Abandoned
-
2008
- 2008-08-05 US US12/222,213 patent/US20090012064A1/en not_active Abandoned
-
2012
- 2012-04-17 US US13/448,538 patent/US8883777B2/en not_active Expired - Fee Related
-
2014
- 2014-10-24 US US14/522,983 patent/US20150045352A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090012064A1 (en) | 2009-01-08 |
WO2001095912A1 (en) | 2001-12-20 |
US8883777B2 (en) | 2014-11-11 |
US20150045352A1 (en) | 2015-02-12 |
CA2412776C (en) | 2011-03-15 |
AU2001264303A1 (en) | 2001-12-24 |
JP4875277B2 (ja) | 2012-02-15 |
EP1297836A4 (en) | 2007-06-13 |
US20030130268A1 (en) | 2003-07-10 |
US20120202798A1 (en) | 2012-08-09 |
KR100838686B1 (ko) | 2008-06-16 |
EP1297836A1 (en) | 2003-04-02 |
CA2412776A1 (en) | 2001-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100838686B1 (ko) | 방출 pH 범위 및/또는 속도 제어 조성물 | |
CA2219991C (en) | Taste masking pharmaceutical composition for oral administration | |
KR101336737B1 (ko) | 4-(4-(3-(4-클로로-3-트리플루오로메틸페닐)-우레이도)-3-플루오로-페녹시)-피리딘-2-카르복실산을 포함하는과증식성 장애 치료용 신규 약학 조성물 | |
US6517871B1 (en) | Bioenhanced formulations comprising eprosartan in oral solid dosage form | |
US20140186450A1 (en) | Gastroresistant pharmaceutical formulations containing rifaximin | |
EP0630233A1 (en) | COMPOSITION FOR ORAL PREPARATIONS. | |
KR20140029554A (ko) | 피르페니돈 및 약학적으로 허용가능한 부형제의 캡슐 제제 | |
CA2529746A1 (en) | Oral extended-release composition | |
US20100136119A1 (en) | Controlled-release preparation containing cilostazol and process for the preparation thereof | |
SG176934A1 (en) | Pharmaceutical composition having improved solubility | |
US10105365B2 (en) | Solid antiviral dosage forms | |
KR20070007133A (ko) | 6-머캅토퓨린의 서방형 제제 | |
KR100381834B1 (ko) | 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법 | |
JPH11139960A (ja) | 医 薬 | |
JP2004525887A (ja) | 新規フェノフィブラート錠剤 | |
KR20070024047A (ko) | 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법 | |
KR101956586B1 (ko) | 약제학적 조성물 및 이의 제조방법 | |
KR20230024389A (ko) | 우티델론의 고체 경구용 제제 | |
JP2813792B2 (ja) | マレイン酸イルソグラジン経口投与用製剤およびその製造法 | |
CN116898808A (zh) | 一种FXIa的药物组合物及其制备方法与医药用途 | |
AU2011244932B8 (en) | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders | |
CN115715766A (zh) | 包含1,3,5-三嗪衍生物或其盐的固体药物组合物 | |
KR20080007543A (ko) | 시클로옥시게나아제-2 저해제를 포함하는 경구투여용 약제및 이의 제조방법 | |
JP2018002659A (ja) | ゲフィチニブを有効成分とする医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130524 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140530 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150515 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160517 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170522 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180516 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190515 Year of fee payment: 12 |